Orthofix Medical, Inc. (OFIX)

Orthofix reported its Third Quarter 2025 financial results in November 2025. In February 2026, the company reported its Fourth Quarter and Full-Year 2025 financial results, provided 2026 financial guidance, and launched new products. In April 2026, Orthofix realigned its spine leadership. In May 2026, Orthofix reported its First Quarter 2026 financial results, announced solutions for pediatric limb reconstruction, and experienced insider selling. Analyst sentiment is cautiously optimistic, with an average price target of $17.25.

Specific details regarding the demand seasonality for Orthofix Medical, Inc.'s products and services were not explicitly provided. Demand might be influenced by factors such as elective surgery schedules and healthcare budgeting cycles.

Orthofix Medical, Inc. is a global medical technology company focused on musculoskeletal healing, providing solutions for spinal and orthopedic conditions. The company operates in two segments: Global Spine, which accounted for 85% of net sales in 2023 and includes bone growth therapies, spinal implants, biologics, and enabling technologies, and Global Orthopedics, which focuses on limb deformity correction, complex limb reconstruction, and fracture repair. The company's structure evolved with its merger with SeaSpine Holdings Corporation in January 2023.

Orthofix Medical, Inc. is headquartered in Lewisville, Texas, with primary offices in Carlsbad, California, and Verona, Italy. The company's global footprint includes facilities and offices in Irvine, California; Toronto, Canada; Sunnyvale, California; Maidenhead, UK; Munich, Germany; Paris, France; and São Paulo, Brazil. Its products are distributed in approximately 68 countries worldwide.

Orthofix Medical is recognized for its focus on musculoskeletal healing and commitment to advancing patient care with innovative solutions. The company emphasizes providing superior solutions to physicians worldwide with a relentless pursuit of quality and product performance. Analyst sentiment towards Orthofix is cautiously optimistic, with a consensus "Hold" rating and an average price target suggesting potential upside.

Institutional investors own 54% of Orthofix Medical, Inc., with the top seven holding 52% of the shares. Rubric Capital Management LP is the largest institutional shareholder with a 9.5% stake. Insiders own 25.88%, and the general public accounts for an 11% stake.